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ABSTRACT:
The advent of a mechanism specific inhibitor imatinib, targeting Bcr-Abl kinase, has 
paved the way for new treatment strategies in chronic myeloid leukaemia (CML). 
However, resistance to imatinib is common in patients and has recently been linked to 
both transforming growth factor-β (TGFβ) and elevated Lyn kinase activity, although 
molecular mechanisms remain largely unknown. Here, using leukaemic MYL cell lines 
derived from CML patients, we show that TGFβ plays a key role in imatinib-resistance 
via direct effects on Lyn ubiquitination and turnover that results in bursts of Lyn kinase 
activity, and identify c-cbl is a candidate E3 ubiquitin ligase. Furthermore, blockade of 
TGFβ signalling activity with the TGFβ receptor kinase inhibitor SB431542 significantly 
reduces Lyn turnover and activation, and subsequently enhances imatinib-mediated 
CML cell death in a proteasomal-dependent manner. Collectively, our data reveals novel 
co-operative mechanisms in CML involving TGFβ and Lyn kinase linked to proteasome 
function and ubiquitination, and thus supports therapeutic approaches that target 
TGFβ pathway activity as a strategy for overcoming imatinib-resistance in CML. 
INTRODUCTION
Chronic myeloid leukaemia (CML) is a disease of 
haematopoietic stem cells and originates from a specific 
chromosomal transfer event that generates a hybrid Bcr-
Abl oncoprotein with tyrosine-kinase activity and cell 
transforming capacity [1]. Recently, a Bcr-Abl kinase 
inhibitor (Imatinib, Gleevac or STI571) has been used 
to treat CML with some success [2]. However, patients 
become resistant mainly due to a small group of immature 
Bcr-Abl +ve stem cells in the bone marrow that have 
stopped dividing, and become refractory to the effects 
of an inhibitor which is only effective against growing 
cells [3]. Mechanisms associated with imatinib-resistance 
include Bcr-Abl point mutations and increased Bcr-Abl 
protein expression [4, 5]. In addition, Bcr-Abl-independent 
mechanisms of resistance have been proposed [6], 
including elevated P-glycoprotein drug efflux [7], and the 
recruitment of other signalling cascades [8]. Most notably, 
several recent studies highlight an emerging role for Lyn 
kinase overexpression and activation in the development 
of imatinib-resistance in CML [9-12], and activated Lyn 
results in elevated levels of the anti-apoptotic protein Bcl-
2, which protects CML cells from imatinib-mediated cell 
lethality [13]. Furthermore, in CML cells, knockdown of 
elevated Lyn expression by siRNA resulted in increased 
apoptosis and enhanced imatinib sensitivity [14].
At present, the precise molecular mechanisms 
responsible for increased Lyn expression and activation 
in CML have not been established, although it is likely 
to involve induction and/or re-wiring of other signalling 
pathways linked to haematopoietic cell function. A prime 
candidate in this regard is transforming growth factor-β 
(TGFβ), which is known to play a vital role in maintaining 
the growth and differentiation balance in haematopoietic 
cells  [15].  In  general,  TGFβ  is  a  robust  inhibitor  of 
committed progenitor cell function, and autocrine 
production of TGFβ maintains haematopoietic stem cell 
quiescence [16]. Several recent studies have attempted to 
unravel the effects TGFβ on leukaemia cell proliferation. 
A  TGFβ/FOXO/Akt  signalling  axis  was  found  to  be 
responsible for imatinib resistance in a CML stem cell Oncotarget 2012; 3:  518-524 519 www.impactjournals.com/oncotarget
population and it was shown that pre-treatment of CML 
stem cells with the TGFβ receptor inhibitor LY364947 
efficiently activated Akt and suppressed FOXO-induced 
cell cycle arrest and apoptosis [17]. Furthermore, this 
study demonstrated that combined treatment with 
LY364947 and Imatinib significantly reduced lethality in 
a CML mouse model and decreased stem cell frequency. 
In support of these data, TGFβ has also been reported as 
a candidate niche factor to maintain haematopoietic stem 
dormancy and hibernation [18]. Collectively, these data 
suggest that blockade of TGFβ signalling activity could 
potentially promote efficient eradication of residual CML 
stem cells, a notion that is also supported the finding that 
Bcr-Abl enhances TGFβ signalling activity in CML cells 
[19].
Interestingly, previous studies have implicated a 
role  for TGFβ  in  regulating  Lyn  function,  and TGFβ 
stimulation over a 30 minutes timeframe caused a rapid 
decrease in cellular levels in Lyn together with a decrease 
in Lyn kinase activity in a prostate cancer cell line [20]. 
Here, we investigated inter-connections between TGFβ 
and Lyn in the MYL cell line derived from a CML patient 
and find that TGFβ stimulation drives rapid ubiquitination 
and proteasomal turnover of Lyn. Interestingly, prolonged 
stimulation results in Lyn protein replenishment and a 
significantly elevated re-bound in the level of Lyn kinase 
activity. Furthermore, we identify the E3 ubiquitin ligase 
c-cbl  as  a  candidate  intermediate  that  drives  TGFβ-
mediated Lyn turnover/activation, and show that blocking 
TGFβ  signalling  activity  reduces  Lyn  activity  and 
concomitantly sensitizes CML cells to imatinib-mediated 
cell death. Therefore, based on this new mechanistic 
insight  we  propose  that  blockade  of  TGFβ  signalling 
activity in combination with the Bcr-Abl inhibitor Imatinib 
could provide a basis for the treatment of drug-resistant 
CML. 
RESULTS AND DISCUSSION
TGFβ-induced  Lyn  ubiquitination  generates 
bursts of Lyn kinase activity in CML cells
Since previous studies have implicated a role for 
both TGFβ activity and Lyn kinase overexpression in 
CML, we examined whether TGF might exert a direct 
influence on Lyn function in MYL cells derived from a 
chronic phase CML patient [10]. Initially, we treated MYL 
cells with TGFβ and probed cellular lysates by western 
blotting with a Lyn antibody to monitor changes in Lyn 
protein  levels.  Unexpectedly,  we  found  a  significant 
decrease in the levels of Lyn after 30 minutes followed by 
a significant increase in Lyn following prolonged 6hours 
stimulation (Figure 1A). Interestingly, in the presence of 
the general ubiquitin-proteasome system inhibitor MG132 
we observed an increase in higher molecular weight Lyn 
reactive bands that was not seen in the presence of the 
type I TGFβ receptor kinase inhibitor SB431542 (Figure 
1A). Quantification also indicates that this rapid decrease 
and then recovery in Lyn protein levels was significantly 
attenuated in cells incubated with MG132 (Figure 1B). 
Since the high molecular weight Lyn reactive species 
were seen primarily in the presence of MG132, we next 
tested whether they might represent ubiquitinated Lyn 
species. There is a clear induction of high molecular 
weight polyubiquitinated Lyn protein that peaks at 1hour 
of stimulation, and this is not seen in cells that were pre-
treated with 10µM SB431542 (Figure 1C). Next, we 
examined whether prolonged stimulation of MYL cells 
with  TGFβ  affects  Lyn  protein  kinase  activity  using 
a  specific  immune  kinase  assay  and  poly(Glu-Tyr)  as 
substrate. Following 30minutes TGFβ stimulation, Lyn 
kinase activity declines rapidly but then recovers again to 
peak after 3hours (Figure 1D). This influence of TGFβ on 
Lyn kinase activity was confirmed by treatment of cells in 
the presence of 10µM SB431542 in which there is a slow 
but steady drop in Lyn activity (Figure 1D).
This induction of Lyn ubiquitination seen 
endogenously in MYL cells was then confirmed using 
ectopic overexpression experiments (Figure 2A). There 
are a number of potential E3 Ubiquitin ligases that might 
connect  cell  surface TGFβ  receptor  activation  to  Lyn 
ubiquitination. Previous studies highlighted dysregulated 
TGFβ signalling in cbl-/- cells [21], as well as oncogenic 
cbl mutations in several myeloid malignancies [22], and 
c-cbl is known to interact with Lyn and drive it Lyn poly-
ubiquitination [23]. Interestingly, we find that TGFβ can 
stimulate cbl-mediated Lyn ubiquitination in a dose-
dependent manner (Figure 2B), as well as induce c-cbl 
mRNA expression (Figure 2C). Therefore, we suggest that 
mechanistically TGFβ drives bursts of Lyn ubiquitination 
and turnover via inducing c-cbl transcription and 
expression.
Inhibition of type TGFβ receptor kinase enhances 
Imatinib mediated CML cell death
Since TGFβ is able to drive bursts of Lyn kinase 
activity, and elevated Lyn kinase has been implicated 
in imatinib-resistance, we next investigated whether 
blockade of TGFβ signaling might influence CML cell 
growth and sensitivity to Imatinib. Cell Cycle analysis 
indicates that addition of TGFβ increases the proportion 
of MYL cells in G0/G1 phase by 5%, concomitant with a 
5% reduction in the S phase population (Figure 3A). In the 
presence of SB431542 alone there is a decrease in the G0/
G1 cell population and a 2% increase in cells in S phase 
indicative also of relatively high autocrine TGFβ activity, 
and an increase of almost 6% in the G2/M population 
compared to TGFβ treated cells (Figure 3A). Therefore, Oncotarget 2012; 3:  518-524 520 www.impactjournals.com/oncotarget
it is apparent that inhibition of TGFβ signalling in MYL 
cells encourages progression through the cell cycle, an 
important observation in the context of dual treatment 
approaches since imatinib is only effective against 
dividing cells. We then used MTS assays to assess whether 
combined treatment with Imatinib and SB431542 could 
influence MYL cell survival. In the presence of Imatinib, 
MYL cell survival gradually falls with increasing doses 
up to 0.1µM, and combined with SB431542 which in this 
instance blocks autocrine TGFβ signaling activity there is 
a significant decrease in cell survival (Figure 3B). We then 
examined whether SB431542 enhanced Imatinib-mediated 
cell death using Poly (ADP-ribose) polymerase (PARP) 
cleavage assays to assess cells undergoing apoptosis. 
There  is  a  significant  reduction  in  un-cleaved  PARP 
(113kDa) in MYL cells exposed for 12 hours to both 
SB431542 and Imatinib combined with a clear increase 
in cleaved PARP at 29kDa (Figure 3C). Finally, we used 
an alternative assay for apoptosis based on changes in 
Annexin-V staining as monitored using flow cytometry. 
Here, cells were pre-treated in the presence/absence 
TGFβ for 1hour to drive Lyn turnover, and combination 
treatment  of  imatinib  with  SB431542  significantly 
enhances apoptosis compared to either imatinib or SB 
treatment alone (Figure 3D). Furthermore, we find that 
pre-treatment with MG132 attenuates the combined 
effect of imatinib and SB431542 implicating the ubiquitin 
proteasome system in this dual additive response, although 
this may be an indirect effect not necessarily related to 
TGFβ-induced Lyn ubiquitination.
In  summary,  we  have  shown  for  the  first  time 
direct inter-connections between TGFβ and Lyn kinase 
in a cell line derived from a CML patient. We find that 
prolonged TGFβ stimulation drives ubiquitination and 
Figure 1: TGFβ-induced Lyn ubiquitination generates a burst of Lyn kinase activity in CML cells. (A) MYL cells were 
serum starved overnight in 0.5% serum-containing media before treatment in the presence/absence MG132 with 1ng/ml TGFβ and/or 
10μM SB431542 as indicated. Cells were lysed and Western blots probed with anti-Lyn and anti-β-Actin antibodies. (B) Blots in Figure 
1A were analysed by densitometric scanning using ImageJ image analysis software, and data are representative of three experiments. (C) 
MYL cells were treated with 1ng/ml TGFβ and/or 10μM SB431542 in the presence of MG132 as indicated, and lysates immunoprecipitated 
with anti-polyubiquitin antibody were separated by Western blotting and probed with anti-Lyn or anti-actin antibodies. (D) MYL cells were 
treated with 1ng/ml TGFβ in the presence/absence 10µM SB431542 as indicated, lysates immunoprecipitated with anti-Lyn and immune 
complexes assayed for Lyn kinase assay using ATP-γP33 and poly(Glu-Tyr) as substrate as described in Materials and Methods. Data are 
representative of two independent experiments performed in triplicate, and expressed as a specific activity in relation to total lyn protein 
levels as determined by anti-Lyn western blotting.Oncotarget 2012; 3:  518-524 521 www.impactjournals.com/oncotarget
rapid turnover of Lyn resulting in Lyn replenishment 
and bursts of Lyn kinase activity. Furthermore, we show 
that  inhibiting  endogenous  TGFβ  signalling  reduces 
Lyn activity and concomitantly encourages exit from 
cell cycle arrest and sensitizes CML cells to imatinib-
mediated cell death. Therefore, our findings highlight new 
mechanistic insight linked to CML disease resistance, and 
suggest that the use of TGFβ inhibitors in combination 
with Imatinib to overcome drug-resistant CML clearly 
warrants further consideration. Our future work will be 
focussed on extending our findings to a range of primary 
cells from imatinib-sensitive and resistant patients to 
confirm clinical significance, and understanding further 
in vivo mechanisms linked to CML pathology as well as 
characterising specific E3 ubiquitin ligases responsible for 
TGFβ-induced Lyn ubiquitination.
MATERIALS AND METHODS
Cell lines, reagents, treatments, and western blot 
analysis
MYL cells were maintained as described previously 
in RPMI supplemented with 10% Foetal Bovine Serum, 
1% Penicillin Streptomycin (p/s), glutamine (200mM). 
HEK-293 cells were maintained in Dulbecco’s modified 
Eagle’s medium containing 10% foetal bovine serum, 1% 
Penicillin Streptomycin (p/s), and glutamine (200mM). 
Lyn cDNA cloned into a pBOS-Flag expression vector was 
obtained from Hiroshi Murakami (Okayama University), 
c-cbl expression vector from Stan Lipkowitz, National 
Institutes of Health, Maryland, and Ubiquitin-His from 
Figure 2: TGFβ stimulates c-cbl-dependent Lyn ubiquitination. (A) TGFβ induces Lyn ubiquitination. HEK293T cells were 
co-transfected with expression plasmids for Lyn and His-tagged Ubiquitin. Cells were put into 2% FCS-containing media overnight before 
TGFβ treatment (1ng/ml) for a range of time between 0-360 minutes, or 10μM SB431532. Cell lysates were incubated overnight with 
nickel-NTA beads, and bound proteins eluted with Laemmli buffer. Samples were separated by SDS-PAGE and Western blots probed with 
anti-His, anti-Lyn or anti-actin antibodies as indicated. (B) HEK293T cells were transfected with Lyn, c-Cbl and Ub plasmids as indicated. 
Cells were maintained in 2% FCS media post-transfection before TGFβ (1ng/ml) or SB431542 (10μM) stimulation for 60 minutes. Lysates 
were incubated with Nickel-NTA beads, and bound proteins eluted with Laemmli buffer. Samples were separated by SDS-PAGE and 
Western blots probed with anti-His, anti-Lyn or anti-actin antibodies as indicated. (C) MYL cells were stimulated with TGFβ (1ng/ml) for 
60minutes. RNA was isolated, reverse transcribed, and and 5ng cDNA utilised as template DNA in qRT-PCR using primers specific for 
c-cbl. Data represent triplicate samples, and are normalised against 18S RNA as an internal control.Oncotarget 2012; 3:  518-524 522 www.impactjournals.com/oncotarget
Sylvie Urbe (Liverpool University, UK). These plasmids 
were used for transient transfection of HEK-293 cells 
using LipoD transfection reagent (SignaGen Laboratories, 
USA). Imatinib mesylate (STI571, Gleevec) was obtained 
from Novartis Pharmaceuticals (Basel, Switzerland), 
and  SB431542  (TGFβ-RI  inhibitor)  from  Tocris  Ltd. 
Antibodies used included anti-Lyn (New England 
Biolabs), anti-ubiquitin (Sigma), anti-Smad3 and anti-
phospho-Smad3 (BD transduction laboratories), anti-His 
(Amersham Biosciences), anti-PARP (Abcam), anti-HA 
(Roche) and anti-β-actin (Sigma). Secondary antibodies 
were HRP-conjugated goat anti-rabbit or goat anti-mouse 
(Sigma). Cell lysis, SDS-PAGE and western blotting 
performed as described previously [19, 24].
Lyn kinase assays
Lyn kinase activity was assessed by 
immunoprecipitation of Lyn followed by an in vitro kinase 
assay of this immune complex in the presence of ATP-γP33 
as described previously [25]. 
Ubiquitination studies
Transfected cells treated with either 20µM MG132 
for 5 hours in DMEM medium containing 2 % FCS and 
treated +/- 5ng/ml TGFβ for 1hr, washed in cold PBS, 
lysed in 1% v/v Igepal-630, 50mM Tris pH 8.0, 150mM 
NaCl, 10% v/v glycerol, 5mM EDTA 1mM NaF, 1mM 
Na3VO4 and protease inhibitors. Lysates were cleared by 
centrifugation and incubated with 0.5µg high affinity anti-
HA or anti-Ub antibody and 20µl of protein-G agarose 
(Sigma) overnight at 4oC. Immune-complexes were 
harvested (2000 rpm; 30 sec), and repeatedly washed using 
0.1% NP-40 LB. Immunoprecipitates were resuspended 
in 15µl Laemelli buffer (+10mM DTT), and analysed by 
Western blotting.
Figure 3: Inhibition of type TGFβ receptor kinase enhances Imatinib mediated CML cell death. (A) MYL cells were 
synchronised with a double thymidine block, then treated with either TGFβ or SB431542 for 12 hours. Cells were fixed in 70% ethanol, 
incubated with propidium iodide and cell cycle status analysed by flow cytometry. Data is representative of three separate experiments 
and was analysed using CFlow Plus software. (B) MYL cells were serum starved in 0.5% serum containing media overnight and treated 
with either a range of Imatinib concentrations between 0-0.1μM or in combination with SB431542, or with TGFβ and SB431542 alone 
as controls. Cell viability was assessed using MTS assays. (C) MYL cells were serum starved overnight in 0.5% serum containing media 
before treatment with 0.3μM Imatinib, 10μM SB431542 or a combination of the two for 6 or 12 hours. Lysates were separated through 
SDS-PAGE, and subsequent Western blots were probed with anti-PARP or anti-actin antibodies. (D) MYL cells were pre-treated +/- 1ng/ml 
TGFβ followed by combination treatments with 0.3μM Imatinib, 10μM SB431542, 20μM MG132 or combinations of these as indicated, 
and cells were incubated for an additional 24hours and cellular apoptosis measured by annexin-V and propidium iodide staining followed 
by flow cytometry analysis. Data are representative of two separate experiments performed in triplicate.Oncotarget 2012; 3:  518-524 523 www.impactjournals.com/oncotarget
Quantitative real-time qPCR
RNA was extracted using the SV Total RNA Isolation 
System (Promega) according to the manufacturer’s 
instructions. To generate cDNA, 0.1µg of RNA was 
reverse transcribed per reaction using reverse transcriptase 
(Amersham) and random primers (Invitrogen) according 
to standard protocols, and gene expression was normalized 
against the housekeeping gene 18S. The reaction mix was 
set up as described previously [26], and cycling conditions 
were 2 minutes at 50°C, 10 minutes at 95°C, 15 seconds at 
95°C repeated 40 times and 60°C for 1 minute. The c-Cbl 
primer/probes were obtained from Applied Biosytems 
(Hs00231981_m1), and reactions were performed using 
an ABI PRISM 7500 thermocycler (Applied Biosystems).
Cell cycle analysis
Cell cycle status was assessed following the staining 
of cells with propidium iodide (PI) and flow cytometry 
analysis. Stained cells were counted on a FACScan flow 
cytometer (Becton Dickinson), and the data obtained was 
analysed using CFlow Plus as described previously [19].
MTS and apoptosis assays
Approximately 5000 cells were seeded into 96 well 
plates in a volume of 100μl per well and grown overnight 
in 0.5% FCS-containing media. Cells were pre-treated 
accordingly, with SB431542 (10µM) or imatinib (10µM) 
prior to the addition of TGFβ. Cells were then left at 37°C 
for 48 hours, and 10μl of the MTS solution (Promega) 
was added to each well. Cells were further incubated for 
3 hours before absorbance readings were taken at 490nm. 
When using flow cytometry to measure apoptosis, cell 
samples were collected by centrifugation (500g; 5min), 
then resupended and stained with Annexin-V and PI dye, 
followed by detection.
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